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a b s t r a c t 
Cerebrovascular reactivity (CVR), which measures the ability of cerebral blood vessels to dilate or constrict in 
response to vasoactive stimuli such as CO2 inhalation, is an important index of the brain’s vascular health. Quan- 
tification of CVR using BOLD MRI with hypercapnia challenge has shown great promises in research and clinical 
studies. However, in order for it to be used as a potential imaging biomarker in large-scale and multi-site stud- 
ies, the reliability of CO2-CVR quantification across different MRI acquisition platforms and researchers/raters 
must be examined. The goal of this report from the MarkVCID small vessel disease biomarkers consortium is to 
evaluate the reliability of CO2-CVR quantification in three studies. First, the inter-rater reliability of CO2-CVR 
data processing was evaluated by having raters from 5 MarkVCID sites process the same 30 CVR datasets using a 
cloud-based CVR data processing pipeline. Second, the inter-scanner reproducibility of CO2-CVR quantification 
was assessed in 10 young subjects across two scanners of different vendors. Third, test-retest repeatability was 
evaluated in 20 elderly subjects from 4 sites with a scan interval of less than 2 weeks. In all studies, the CO2 
CVR measurements were performed using the fixed inspiration method, where the subjects wore a nose clip and 
a mouthpiece and breathed room air and 5% CO2 air contained in a Douglas bag alternatively through their 
mouth. The results showed that the inter-rater CoV of CVR processing was 0.08 ± 0.08% for whole-brain CVR 
values and ranged from 0.16% to 0.88% in major brain regions, with ICC of absolute agreement above 0.9959 
for all brain regions. Inter-scanner CoV was found to be 6.90 ± 5.08% for whole-brain CVR values, and ranged 
from 4.69% to 12.71% in major brain regions, which are comparable to intra-session CoVs obtained from the 
same scanners on the same day. ICC of consistency between the two scanners was 0.8498 for whole-brain CVR 
and ranged from 0.8052 to 0.9185 across major brain regions. In the test-retest evaluation, test-retest CoV across 
different days was found to be 18.29 ± 17.12% for whole-brain CVR values, and ranged from 16.58% to 19.52% 
in major brain regions, with ICC of absolute agreement ranged from 0.6480 to 0.7785. These results demonstrated 
good inter-rater, inter-scanner, and test-retest reliability in healthy volunteers, and suggested that CO2-CVR has 
suitable instrumental properties for use as an imaging biomarker of cerebrovascular function in multi-site and 
longitudinal observational studies and clinical trials. 
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1. Introduction 
Cerebrovascular reactivity (CVR), which denotes the ability of cere- 
bral blood vessels to dilate or constrict in response to vasoactive stim- 
uli, is an important index of the brain’s vascular health. As a dynamic 
property of the cerebral blood vessels, CVR provides vital information 
of vascular reserve that is complementary to steady-state vascular pa- 
rameters, such as cerebral blood flow (CBF) and cerebral blood vol- 
ume (CBV). CVR has been shown to be a sensitive biomarker in var- 
ious brain diseases and conditions such as dementia ( Cantin et al., 
2011 ; Silvestrini et al., 2006 ; Sur et al., 2020 ; Yezhuvath et al., 
2012 ), arterial stenosis ( De Vis et al., 2015b ; Donahue et al., 2013 ; 
Gupta et al., 2012 ; Mandell et al., 2008 ; Mikulis et al., 2005 ), stroke 
( Geranmayeh et al., 2015 ; Krainik et al., 2005 ), small vessel disease 
( Greenberg, 2006 ; Marstrand et al., 2002 ), mild cognitive impairment 
( McKetton et al., 2019 ; Sur et al., 2020 ; van der Thiel et al., 2019 ), mul- 
tiple sclerosis ( Marshall et al., 2014 ; Pelizzari et al., 2020 ), brain tumors 
( Fierstra et al., 2016 ; Pillai and Zaca, 2011 ; Zaca et al., 2014 ), traumatic 
brain injury ( Chan et al., 2015 ; Kenney et al., 2016 ), substance abuse 
( Han et al., 2008 ), and normal aging ( De Vis et al., 2015a ; Gauthier et al., 
2013 ; Lu et al., 2011 ). Additionally, CVR can also be used to account for 
vascular contributions in blood-oxygenation-level-dependence (BOLD) 
signals in functional MRI studies to obtain a more quantitative measure 
of task-induced neural activities ( Chen and Gauthier, 2021 ; Davis et al., 
1998 ; Hoge et al., 1999 ; Kannurpatti and Biswal, 2008 ; Liu et al., 2013a ; 
Liu et al., 2013b ; Restom et al., 2008 ; Song et al., 2016 ; Tsvetanov et al., 
2015 ). 
CVR is typically obtained by inducing a vasoactive challenge to 
the participant while monitoring changes in hemodynamic MRI sig- 
nals. Among the available vasoactive challenges including the injection 
of acetazolamide, inhalation of hypercapnic gas, and breath-holding, 
hypercapnia inhalation has been increasingly used in recent literature 
due to its potency in causing vasodilation, rapid onset and cessation 
of the effect, as well as recent advances in MRI-compatible gas deliv- 
ery apparatus ( Lu et al., 2014 ; Slessarev et al., 2007 ; Tancredi et al., 
2014 ; Wise et al., 2007 ; Yezhuvath et al., 2009 ). For MRI acquisition, 
although CBF and CBV techniques have been utilized to monitor hemo- 
dynamic changes upon the vasoactive challenge ( Davis et al., 1998 ; 
Donahue et al., 2014 ; Donahue et al., 2009 ; Hoge et al., 1999 ; Hua et al., 
2011 ), the BOLD sequence is by far the most widely used acquisition 
technique due to its superior signal-to-noise ratio (SNR) and wide avail- 
ability relative to CBF and CBV MRI techniques. Therefore, there is a 
surging interest to use BOLD fMRI with hypercapnia challenge to quan- 
tify CVR in research and clinical studies. However, before its wider ap- 
plication in large-scale studies which are typically based on a multi-site 
setting, e.g. the MarkVCID study ( Lu et al., 2021 ), reliability of CO2-CVR 
in terms of sessions, raters, and scanner vendors needs to be examined. 
The goal of the present report, performed as part of the MarkVCID 
cerebral small vessel disease biomarkers consortium, is to systemati- 
cally address these questions in a series of three instrumental valida- 
tion studies. In the first inter-rater reliability study, we evaluated the 
rater-dependence of a cloud-based CVR data processing pipeline, which 
is essential for broad availability of the CO2-CVR technique. In the sec- 
ond inter-scanner study, we conducted a multi-vendor comparison study 
to evaluate the reproducibility of CO2-CVR on two MRI platforms (on 
the same day). In the third study, we conducted a test-retest repeatabil- 
ity study to evaluate CVR across different days (on the same scanner). 
To ensure that the test-retest repeatability results are generalizable for 
multi-center trials, Study 3 was conducted at different MarkVCID sites. 
2. Methods 
2.1. General 
Five MarkVCID sites, all located in the United States, participated 
in this study. All sites were equipped with 3T whole-body MRI sys- 
tems. Table 1 lists demographic information of the participants in all 
sites by studies. The MarkVCID Consortium harmonized the study pro- 
tocol and it was approved by the institutional review board (IRB) of 
each site, specifically the Johns Hopkins Medicine IRB, the University 
of Kentucky IRB, the University of New Mexico IRB, the University of 
Southern California IRB, and the University of Texas Health San Anto- 
nio IRB. Informed written consent was obtained from each participant. 
The participants included in this study had no history of neurologic or 
psychiatric diseases. 
2.2. CO2-CVR acquisition 
The CO2 inhalation setup and procedure followed the procedure de- 
scribed by the MarkVCID consortium ( Lu et al., 2021 ). Specifically, sub- 
jects were fitted with a mouthpiece and a nose-clip, and mild hyper- 
capnia air (5% CO2, 21% oxygen, and 74% nitrogen) was administered 
using a Douglas bag, with a valve to switch between room-air and hyper- 
capnic air ( Lu et al., 2014 ). After the initial 15s of room air breathing, 
subjects breathed 50s of hypercapnic air and 70s room-air alternatively 
for 3 times, followed by an additional 45s room air, for a total duration 
of 420 seconds. CO2 concentration in the exhaled air was sampled at 100 
Hz and the resulting CO2 trace was recorded using capnography (NM3, 
Philips, Pittsburgh, PA). BOLD fMRI images were continuously acquired 
during the entire 420-second period. The scan parameters were: gradi- 
ent echo EPI, in-plane resolution = 3.4 × 3.4 mm 2 , matrix size = 64 × 64, 
34-36 axial slices (depending on MRI scanner model) with 3.8mm slice 
thickness for whole brain coverage, repetition time (TR) = 1500ms, echo 
time (TE) = 21ms, flip angle (FA) = 90°, 281 volumes with 6 dummy 
volumes for scanner stabilization. These parameters were chosen based 
on our previous technical development studies to minimize artifact in 
CVR results. Specifically, Based on recent theoretical and experimental 
evidence ( Ravi et al., 2016 ), the use of a TE of 21ms, which is shorter 
than those used in fMRI (typically 30-45ms), can minimize the artifi- 
cially negative CVR values in the ventricle regions. A high resolution 3- 
D T1-weighted multi-echo magnetization-prepared rapid-acquisition-of- 
gradient-echo (ME-MPRAGE) was performed (1 × 1 × 1mm 3 voxel size, 
4 echoes, TR/TE/ ΔTE/TI = 2530/1.66/1.9/1300 ms for Philips scan- 
ner and 2530/1.64/1.86/1100 or 1200 ms for Siemens scanners) for 
anatomic reference ( Lu et al., 2021 ). 
2.3. CO2-CVR processing pipeline 
CVR data processing was performed using a cloud-based on- 
line processing tool referred to as CVR-MRICloud (Version 5, 
https://braingps.mricloud.org/cvr.v5 ) ( Baker et al., 2019 ). With this 
cloud-based processing tool, the users uploaded the de-identified CVR 
data files to the cloud server, including the BOLD image files, the CO2 
trace file (after manually trimmed to remove extra recording periods 
before the mouthpiece was put on and after it was taken off), and 
the T1-MPRAGE image (average of the ME-MPRAGE images across all 
echoes) which allow the normalization of CVR results to the standard 
MNI space. Next, the server performed the CVR processing automat- 
ically. Once completed, the users downloaded a set of output results 
from the server, including the CVR maps and CVR values of the whole 
brain and different anatomic brain regions. 
The CVR processing performed on the cloud server followed the 
method established previously ( Liu et al., 2019 ; Lu et al., 2014 ; 
Yezhuvath et al., 2009 ). Briefly, the BOLD data were first motion cor- 
rected and smoothed by an 8mm Gaussian kernel. The end-tidal CO2 
(EtCO2) curve was extracted from the CO2 trace using an automatic 
algorithm to identify the peak CO2 of each breath. The EtCO2 curve 
was time-shifted to align with the whole-brain BOLD signal time course 
and then used as a regressor for a voxel-wise linear regression with the 
BOLD data, which yields the CVR map. The CVR map was then coreg- 
istered to the MPRAGE-image-space and transformed to the MNI-space 
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Table 1 
Scanner and demographic information of the study. 
Site 1 Site 2 Site 3 Site 4 Site 5 
Inter-rater reliability 
Scanner Philips Achieva Siemens Trio Siemens Prisma Siemens Trio –
N 15 6 7 2 –
M/F 7M/8F 2M/4F 2M/5F 0M/2F –
Age 69.5 ± 4.9 72.4 ± 5.7 68.8 ± 3.6 78.4 ± 3.6 –
Inter-scanner reproducibility 
Scanner Philips Achieva and Siemens Prisma – – – –
N 10 – – – –
M/F 7/3 – – – –
Age (y) 23.9 ± 2.4 – – – –
Test-retest repeatability 
Scanner Philips Achieva Siemens Trio Siemens Prisma – Siemens Trio 
N 6 4 4 – 6 
M/F 0M/6F 1M/3F 1M/3F – 1M/5F 
Age (y) 64.3 ± 5.6 78.9 ± 2.9 75.0 ± 5.1 – 67.9 ± 3.9 
using SPM. Finally, the segmented MPRAGE image was used to calcu- 
late ROI CVR values by applying the anatomical ROI masks to the BOLD 
data to obtain ROI-time-courses for ROI CVR computation. The final 
CVR value is written in the units of % BOLD signal change per mmHg 
of EtCO2 (%/mmHg). Brain regions investigated included gray matter 
ROIs of frontal lobe, parietal lobe, temporal lobe, limbic lobe, occipi- 
tal lobe, insular, basal ganglia and thalamus ( Wu et al., 2016 ), cerebral 
white matter ROI, as well as calculation of a whole-brain CVR value that 
includes both gray and white matters. 
2.4. Inter-rater reliability (Study 1) 
The inter-rater reliability indicates the degree of agreement among 
independent raters assessing the same dataset. The objective of this anal- 
ysis was to investigate whether different raters reported consistent CVR 
results obtained in the same sample. This sample included 30 partici- 
pants imaged with the above-described CO2-CVR protocol at four dif- 
ferent sites (Sites 1, 2, 3, and 4). The 30 CO2-CVR datasets were sent to 
all five participating sites (Sites 1, 2, 3, 4, and 5) for analysis. Writ- 
ten instructions and a webinar were given to the investigators from 
each participating site for training (Training materials are published 
at https://markvcid.partners.org/consortium-protocols-resources ). One 
rater from each site analyzed the datasets independently using the CVR- 
MRICloud processing pipeline and shared outputs with the lead site (site 
1), resulting in 5 raters × 30 subjects CVR measures. 
2.5. Inter-scanner reproducibility (Study 2) 
The inter-scanner reproducibility indicates the ability to obtain sim- 
ilar observations using the same methodology on different scanners. To 
evaluate the reproducibility of CO2-CVR on different MRI platforms, 
a cross-vendor comparison was performed at the lead site (Site 1). 
Ten healthy subjects (3 females, age 23.9 ± 2.4y) participated in this 
study. Each subject was scanned on a Philips (Achieva) and a Siemens 
(Prisma) 3 T scanner within a 2.5-hour period. On each scanner, CVR 
scans were performed twice with repositioning. The order of the scan- 
ners was counterbalanced across subjects. The imaging acquisition and 
analysis protocol followed that described earlier, resulting in 2 ven- 
dors x 10 subjects x 2 repetitions CVR measures. To reduce the ef- 
fects of physiological variations ( Bright et al., 2011 ; Hou et al., 2020 ), 
the CVR values were further corrected for basal and ΔEtCO2 differ- 
ences between repetitions and across the scanners using the associ- 
ation between them established previously ( Hou et al., 2020 ), given 
by CVR 2, corr = CVR 2 + 0.0036(EtCO2 basal,2 - EtCO2 basal,1 ) + 0.0072 
( ΔEtCO2 2 - ΔEtCO2 1 ). 
2.6. Test-retest repeatability (Study 3) 
Test-retest repeatability indicates the degree of agreement of CVR 
measurements on the same scanner but on different days. To evaluate 
the test–retest repeatability of CO2-CVR on different days, four partic- 
ipating sites (Sites 1, 2, 3, and 5) recruited a total of 20 individuals. 
Each participant received two CO2-CVR scans using the same scanner 
and protocol with a gap 4 to 13 days (average 8.9 ± 2.9 days). The num- 
ber of the subjects from each site are shown in Table 1 . This study 
was performed in a multi-site fashion to simulate conditions in a multi- 
center trial where sites will have varying levels of prior experience with 
CVR-specific procedures (e.g., placement of mouthpiece and switching 
of gas). The participants in this test-retest study are also representative 
in age of individuals expected to be enrolled in a future small vessel dis- 
ease trial. ( Table 1 ). On-site training of the CVR experiment procedure 
was given at each participating site by the lead site prior to the start 
of the study. Participating sites shared the de-identified data with the 
lead site for analysis. One subject from Site 2 was excluded due to the 
absence of CO2 inhalation in the first scan, and another subject from 
Site 3 was excluded due to mouthpiece displacement (resulting in CO2 
trace recording failure) during the second scan, so these two subjects 
were excluded from the test-retest analysis, resulting in 18 subjects x 2 
repetitions CVR measures across 4 sites. Basal and ΔEtCO2 differences 
between the tests were also accounted for ( Hou et al., 2020 ). 
2.7. Statistical analyses 
All statistical analyses were performed using Matlab and visual- 
ized using Excel. Regression analysis and Bland-Altman ( Bland and Alt- 
man, 1986 ) plot were used to visualize the agreement of whole-brain 
CVR values obtained from different sites (inter-rater reliability study), 
scanners (inter-scanner reproducibility study) and sessions (test-retest 
repeatability study). Variability was assessed by coefficient of vari- 
ance (CoV), given by standard deviation across measures divided by 
mean values. Intraclass correlation coefficient ( Shrout and Fleiss, 1979 ) 
(ICC) were used to evaluate the whole-brain CVR and ROI CVR val- 
ues. Specifically, ICC using a 2-way (same raters) random-effects model 
(same participants) with single measure and absolute agreement form 
(noted as ICC AA ) was calculated for CVR values obtained from different 
sites (inter-rater reliability study) and sessions (test-retest repeatability 
study). ICC using a 2-way random-effects model with single measure 
and consistency form (noted as ICC C ) was calculated for CVR values 
obtained from different scanners (inter-scanner reproducibility study) 
considering systematic error between them. In the inter-scanner repro- 
ducibility study, two measures from each scanner were averaged to re- 
duce physiological variation in the inter-scanner comparison, and addi- 
tional single-site inter-session reliability evaluation was performed for 
each scanner by calculating inter-session CoV and ICC AA using the two 
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Figure 1. Comparisons of whole-brain CVR obtained from five different sites in the inter-rater reliability study (Study 1). Scatterplots are shown in the upper triangle 
panel with linear regression line in black and identity line as dashed gray line. Bland-Altman plots are shown in the lower triangle panel with black lines indicate 
mean and dashed lines indicates 95% confidence interval. Each blue dot represents one subject. 
whole-brain CVR measures obtained from each scanner. ICC values less 
than 0.5, between 0.5 and 0.75, between 0.75 and 0.9, and more than 
0.90 were considered to be poor, moderate, good, and excellent, respec- 
tively ( Koo and Li, 2016 ). For the inter-scanner reproducibility study 
and the test-retest repeatability study, paired t-test was also used to com- 
pare the repeated measures. A p < 0.05 was considered to be significantly 
different. 
3. Results 
3.1. Inter-rater reliability 
Figure 1 illustrates the whole-brain CVR values of 30 individuals 
processed by independent raters of the five participating sites. Visual 
inspection suggested good agreement across the sites. Inter-rater CoV 
was 0.08 ± 0.08% for whole-brain CVR values, and ranged from 0.16 % 
to 0.88 % in major brain regions (see Table 2 ). ICC AA of whole-brain CVR 
measures generated by the five sites was found to be 0.9999, p < 0.0001, 
indicating excellent reliability, i.e. a very strong agreement, between 
the different raters (i.e. sites) when using the CVR-MRICloud analysis 
pipeline on the same CO2-CVR datasets. ICC AA of regional CVR values 
generated by the five sites ranged from 0.9959 to 0.9999 (see Table 2 ). 
3.2. Inter-scanner reproducibility 
Figure 2 a showed the CVR maps obtained from a representative sub- 
ject at each session of each scanner. Visual inspection suggested good 
agreement between the scanners. Scatter plot and Bland-Altman plot of 
whole-brain CVR for 10 individuals imaged at two different scanners 
are shown in Figure 2 b and 2 c, respectively. Mean whole-brain CVR of 
the 10 healthy young subjects was 0.133 ± 0.029 % ΔBOLD/mmHg and 
0.126 ± 0.025 % ΔBOLD/mmHg from the Philips scanner and Siemen 
scanner, respectively, with no significant difference between them 
(p = 0.16). Inter-scanner CoV was 6.90 ± 5.08% for whole-brain CVR 
values, and ranged from 4.69 % to 12.71 % in major brain regions (see 
Table 2 ). ICC C of whole-brain CVR measures from the two scanners was 
found to be 0.8498, p = 0.0005. ICC C of regional CVR values between 
two scanners ranged from 0.8052 to 0.9185 (see Table 2 ), indicating 
good to excellent reproducibility. 
Mean basal EtCO2 of the 10 subjects was 38.42 ± 3.57 mmHg and 
39.15 ± 3.57 mmHg from the Philips scanner and Siemens scanner, 
4 
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Table 2 
Summary of the inter-rater, inter-scanner and inter-session reproducibility of the study. 
Whole-brain Frontal Parietal Temporal Limbic Occipital Insula BasalGang Thalamus White matter 
Inter-rater reliability 
CoV (%) 0.08 ± 0.08 0.34 ± 0.95 0.50 ± 1.56 0.49 ± 1.03 0.33 ± 0.35 0.88 ± 0.92 0.21 ± 0.21 0.22 ± 0.37 0.16 ± 0.11 0.41 ± 1.17 
ICC AA 0.9999 0.9977 09976 0.9995 0.9970 0.9999 0.9999 0.9999 0.9997 0.9972 
Inter-scanner reproducibility 
CoV (%) 6.90 ± 5.08 7.99 ± 5.93 8.21 ± 6.61 7.53 ± 5.56 8.46 ± 7.87 7.92 ± 6.96 12.71 ± 13.32 10.27 ± 9.56 4.69 ± 4.39 12.04 ± 8.01 
ICC C 0.8498 0.9185 0.8528 0.8052 0.8872 0.8068 0.8364 0.9175 0.8687 0.6592 
Test-retest repeatability 
CoV (%) 17.09 ± 16.28 15.92 ± 13.29 18.14 ± 10.89 16.66 ± 14.60 17.82 ± 16.05 19.95 ± 12.23 16.98 ± 17.17 17.45 ± 19.20 18.58 ± 16.59 22.65 ± 20.45 
ICC AA 0.6568 0.7658 0.7427 0.7097 0.7281 0.6375 0.7542 0.7729 0.7139 0.4506 
Figure 2. Comparisons of whole-brain CVR obtained from two scanners in the inter-scanner reproducibility study (Study 2). (a) CVR maps of a representative subject 
at different sessions of different scanners. (b) Scatterplot of the whole-brain CVR measures with linear regression line in black and identity line as dashed gray line. 
(c) Bland-Altman plot of the whole-brain CVR measures with black lines indicate mean and dashed lines indicates 95% confidence interval. Each dot represents data 
from one subject. 
respectively. Mean EtCO2 change ( ΔEtCO2) in response to the 5% 
CO2 inhalation was 9.59 ± 1.68 mmHg and 9.47 ± 1.26 mmHg, respec- 
tively. Mean whole-brain BOLD percent signal change (% ΔBOLD) due 
to CO2 inhalation was 1.31 ± 0.37% and 1.23 ± 0.25%, respectively. No 
significant inter-scanner differences were found for these parameters 
(p > 0.24). Inter-scanner CoV and ICC C of these measures from the two 
scanners are shown in Table 3 . 
Additionally, same-day inter-session (with repositioning) analysis in 
the 10 subjects showed that for whole-brain CVR measures, inter-session 
CoV was 6.30 ± 8.97% for the Philips scanner, and 7.39 ± 7.03% for the 
Siemens scanner, with no significant difference between them (p = 0.86). 
Inter-session ICC AA was 0.8744, p < 0.0001 for the Philips scanner, and 
0.7781, p = 0.001 for the Siemens scanner. For the Philips sessions, same 
day inter-session CoV was 1.59 ± 1.51%, 5.95 ± 6.44% and 9.58 ± 6.14% 
5 
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Table 3 
Summary of the basal EtCO2, ΔEtCO2 and ΔBOLD results in the inter- 
scanner and inter-session reproducibility studies. 
Basal EtCO2 (mmHg) ΔEtCO2 (mmHg) % ΔBOLD (%) 
Inter-scanner reproducibility 
CoV (%) 3.00 ± 2.13 6.47 ± 3.74 11.43 ± 8.82 
ICC C 0.8670 0.7215 0.6886 
Test-retest repeatability 
CoV (%) 18.29 ± 17.12 18.79 ± 11.39 18.51 ± 17.30 
ICC AA 0.6498 0.7152 0.7429 
for basal EtCO2, ΔEtCO2 and % ΔBOLD, respectively, with ICC AA of 
0.9127, 0.7845 and 0.9359, respectively. For the Siemens sessions, same 
day inter-session CoV was 2.63 ± 2.54%, 6.38 ± 4.28% and 14.34 ± 11.56% 
for basal EtCO2, ΔEtCO2 and % ΔBOLD, respectively, with ICC AA of 
0.7571, 0.7890 and 0.5840, respectively. No significant differences be- 
tween the ICC values of the two scanners were found for any of these 
parameters (p > 0.19). 
3.3. Test-retest repeatability 
Figure 3 illustrates test and retest whole-brain CVR measures in 18 
subjects across 4 sites. Mean whole-brain CVR of the 18 elderly subjects 
was 0.109 ± 0.037 % ΔBOLD/mmHg and 0.111 ± 0.040 % ΔBOLD/mmHg 
from the test-retest scans, respectively, with no significant difference 
between them (p = 0.90). Test-retest CoV was 17.09 ± 16.28% for whole- 
brain CVR values, and ranged from 15.92% to 22.65% in major brain 
regions (see Table 2 ). ICC AA between test and retest whole-brain CVR 
measures was found to be 0.6568, p = 0.0014. ICC AA of regional CVR 
values between the two measures ranged from 0.4506 to 0.7729 (see 
Table 2 ), indicating moderate to good repeatability in whole-brain and 
gray matter regions. There was not a site effect in the CoV values for the 
four sites. 
Mean basal EtCO2 of the 18 subjects was 38.91 ± 8.08 mmHg 
and 40.82 ± 5.59 mmHg from the test-retest scans, respectively. Mean 
ΔEtCO2 was 8.72 ± 2.64 mmHg and 8.79 ± 2.67 mmHg, respectively. 
Mean % ΔBOLD was 0.80 ± 0.36% and 0.91 ± 0.39%, respectively. 
No significant test-retest differences were found for these parame- 
ters (p > 0.24). Test-retest CoV was 7.12 ± 17.0%, 16.37 ± 15.80% and 
32.14 ± 241.85% for basal EtCO2, ΔEtCO2 and % ΔBOLD, respectively, 
with ICC AA of 0.4666, 0.5392 and 0.4919, respectively. 
4. Discussion 
In the present work we performed a series of studies to evaluate 
the variability, reliability and reproducibility of CVR quantification us- 
ing BOLD MRI with hypercapnia inhalation, which provides impor- 
tant benchmarks for CO2-CVR as a quantitative biomarker for the fu- 
ture clinical studies. We focused on instrumental validation of three 
biomarker properties that would be essential to applying CVR to a large 
multi-center trial: inter-rater reliability, inter-scanner reproducibility, 
and test-retest repeatability. 
4.1. Inter-rater reliability 
Inter-rater reliability was evaluated by comparing the quantitative 
CVR values obtained by raters at five different sites analyzing the same 
CO2-CVR data. With written instructions and a training webinar, all sites 
were able to process the CO2-CVR data independently using the CVR- 
MRICloud analysis pipeline. Our results showed that ICC of absolute 
agreement of CVR values across all participating sites was above 0.997 
for whole-brain and major brain regions, reflecting excellent inter-rater 
reliability in CO2-CVR quantification. The variability in the CVR results 
originates from a manual step in the processing pipeline, which involves 
the selection of the segment of the CO2 trace to be used. Slight varia- 
tions in this “CO2 trimming ” step, such as how much extra recording to 
be included before the first CO2 inhalation period and after the last CO2 
inhalation period decided by each rater, could affect the determination 
of the optimal time-shift between EtCO2 and BOLD signal time courses, 
which in turn influences the CVR value. However, our results suggested 
that this rater-dependence has minimal effects in CVR quantification. 
There has been no study in literature that examined the inter-rater reli- 
ability of CO2-CVR quantification previously, so our study provided the 
first reference for the reliability of CO2-CVR quantifications using the 
CVR-MRICloud tool ( Baker et al., 2019 ). 
4.2. Inter-scanner reproducibility 
Inter-scanner reliability was evaluated by comparing quantitative 
CVR values obtained from a group of young individuals scanned on 
two different MRI scanners on the same day. Standardization of MRI 
protocols across vendors is the first step in virtually all MRI techniques 
for large-scale, multi-site studies ( Jack et al., 2008 ). Due to the differ- 
ences in hardware specifications and software programming environ- 
ments across scanners, it is not possible to match every parameter be- 
tween the BOLD MRI protocols of the two vendors. For the BOLD MRI 
sequence, the most important components are TR, TE and FA. We used 
the harmonized CVR protocols of the MarkVCID study ( Lu et al., 2021 ), 
where TR/TE/FA are identical across vendors and the other parameters 
are also maximally consistent. Whole-brain CVR measures were found 
to be highly consistent between the Philips and Siemens systems, with 
ICC C of 0.85 and CoV of 6.9%, which is comparable to the same-day 
within scanner, inter-session ICC AA and CoV obtained from the same 
subjects. This inter-scanner CoV of 6.9% for BOLD CVR is slightly higher 
than the anatomic measures, such as brain volume (around 4% for 
whole brain measures ( Huppertz et al., 2010 )) and ADC (around 5% 
( Magnotta et al., 2012 )), but is lower than other functional measures, 
such as ASL (about 15% ( Mutsaerts et al., 2015 )) and functional MRI 
(about 20% ( Friedman et al., 2006 )). If using ASL CoV as reference, 
both whole-brain and regional CVR showed excellent inter-scanner re- 
producibility. To our knowledge, this is the first report of inter-scanner 
variability of CVR quantification. These results support the validity to 
pool data from multiple sites when using the MarkVCID CVR protocol 
( Lu et al., 2021 ) without increasing the heterogeneity of the imaging 
measurements. 
4.3. Test-retest repeatability 
Test-retest repeatability was evaluated by comparing CVR values ob- 
tained using the same MRI scanners on different days within an interval 
of < 2 weeks, an interval in which an individual’s vascular disease is un- 
likely to change. The evaluation of test-retest reliability of CVR measure- 
ments is critical for longitudinal studies, as it is important to interpret 
longitudinal changes observed with reference to intra-subject variations 
due to normal physiological variations and MRI acquisition differences 
such as subject and imaging slice positioning, shimming, and operator 
technique. Our results showed that test-retest CoV was about 17% of 
whole brain CVR and 16-20% of regional CVR across different sites, with 
ICC of absolute agreement to be 0.66 for whole-brain CVR and 0.65- 
0.78 for regional CVR in gray matter, when measured on different days 
within a two-week interval. These CoV values were higher than those 
observed in Study 2 ( ∼7%), which were obtained by a single-site (i.e. 
the lead-author’s site) on the same day, but compared with typical fMRI 
measures, they are considered good. A previous study showed a CoV of 
about 11% and ICC of about 0.75 for CO2 CVR measured in 10 young 
subjects at a single site 3T scanner with 2-days interval ( Leung et al., 
2016 ). A single-site study on 19 healthy volunteers reported ICC of 0.81 
and 0.66 for gray matter and white matter CVR, respectively, using a 
1.5T scanner with a median range of 15 days apart ( Kassner et al., 2010 ). 
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Figure 3. Comparisons of whole-brain CVR obtained from different days in the test-retest repeatability study (Study 3). (a) CVR maps of one representative subject 
from each site at different days. (b) Scatterplot of the whole-brain CVR measures with linear regression line in black and identity line as dashed gray line. (c) 
Bland-Altman plot of the whole-brain CVR measures with black lines indicate mean and dashed lines indicates 95% confidence interval. Each dot represents data 
from one subject. Data from different sites are shown in different colors. 
Another single-site study on 15 healthy subjects reported CoV of 11.7–
70.2% for gray matter CVR and 27.5–141.0% for white matter CVR in 
various brain regions using similar hypercapnia inhalation paradigm on 
a 1.5T scanner in two separate visits ( Thrippleton et al., 2018 ). 
The higher CoV observed in Study 3 relative to the inter-scanner 
variability shown in Study 2 may be attributed to several causes. Dif- 
ferences could reflect actual day-to-day variability over the interscan 
interval of up to 2 weeks. The correction of basal and ΔEtCO2 helped 
to reduce the day-to-day variation of EtCO2, as without this correction, 
CoV and ICC AA of the whole-brain CVR in Study 3 was 18.66 ± 17.33% 
and 0.4859, respectively. However, there are other sources that con- 
tribute to the day-to-day variability. In particular, we did not control 
the participants’ uptake of vasoactive drugs or beverages prior to the 
MRI scan. For example, it is known that caffeine can reduce CBF by up 
to 25% ( Xu et al., 2015 ), thus consumption of coffee may alter the mea- 
sured CVR value. Second, older subjects may reveal a higher inter-scan 
CoV due to a higher tendency to move or otherwise not comply with 
instructions (e.g. opening their mouths) as well as potentially greater 
underlying day-to-day variations in brain physiology. Finally, CO2-CVR 
testing requires the delivery of CO2 gas mixture inside the MRI scan- 
ner as well as recording of end-tidal CO2 trace. Thus, the skill level of 
the experimenter may play a role in the quality of the data (e.g. when 
the mouthpiece is not placed comfortably, the subject may have greater 
motion). This can affect the success rate and lead to data exclusion due 
to technical issues related to CO2 delivery and recording. It should also 
be mentioned that the CoV of CVR is much smaller than the CoV of 
% ΔBOLD in both the inter-scanner and test-retest studies. This is be- 
cause the variations in BOLD signal changes are largely attributed to 
EtCO2 variations, especially ΔEtCO2 variations. Therefore, the calcu- 
lated CVR values, which accounted for EtCO2 variations, have smaller 
CoV than % ΔBOLD alone. 
Nonetheless, the observed CoV of approximately 17% is within the 
range of previous studies, and is less variable than typical task-fMRI 
measures ( Clement and Belleville, 2009 ; Gountouna et al., 2010 ). Im- 
portantly, it should be emphasized that disease-related differences in 
CVR are often greater than 50% ( Cantin et al., 2011 ; Sur et al., 2020 ; 
Yezhuvath et al., 2012 ). Thus, CVR still possesses the sensitivity in de- 
tecting pathological effects in brain diseases. Assuming a 15% difference 
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in whole-brain CVR between cognitive impaired patients and healthy 
controls ( Sur et al., 2020 ), with the CoV of 17%, 20 subjects are needed 
for each group to detect a significant group difference with a power 
of 0.8. Similarly, assuming a 25% difference in CVR between multiple 
sclerosis patients and healthy controls ( Marshall et al., 2016 ), 8 sub- 
jects are needed for each group to detect a significant group difference 
with a power of 0.8. In future clinical trials, test-retest variability can 
be further reduced by improvements in experimental procedures such 
as control of uptake of vasoactive drugs and/or beverages prior to the 
MRI scan as well as enhanced training of personnel performing the CVR 
MRI measurement. 
There are a few limitations of this study. First, the sample size of 
some sites in Study 3 is considered small. Therefore, no comparisons 
among the individual sites were performed due to this sample size lim- 
itation. Second, we focused on the reproducibility of CVR values, but 
did not study the CO2 bolus transit and response time which can also be 
a sensitive index in cerebrovascular diseases, especially in large vessel 
diseases. There are a few advanced CVR analysis methods that could be 
evaluated, which yield transit/delay maps and even functional connec- 
tivity maps ( Bhogal et al., 2015 ; Blockley et al., 2011 ; Donahue et al., 
2016 ; Hou et al., 2019 ). It should also be noted that there are two 
categories of CO2 delivery for CVR mapping ( Liu et al., 2019 ), which 
are the fixed CO2 concentration in the inspired gas ( Lu et al., 2014 ; 
Tancredi et al., 2014 ) and fixed CO2 concentration in the exhaled air 
( Slessarev et al., 2007 ; Wise et al., 2007 ). In this study we only eval- 
uated the CVR mapping method using fixed CO2 concentration (5%) 
in the inspired gas. Compared with the fixed exhaled CO2 concentra- 
tion, the fixed inspiration method is less expensive, involves less train- 
ing and preparation for both the researcher and the participant, and 
troubleshooting is simpler. Therefore, it is thought to be more suited for 
multi-site studies where researchers are not always experienced with 
CVR mapping. In the MarkVCID study, the gas delivery packages were 
disseminated to all participating site by the lead site, following the item 
list published previously ( Lu et al., 2014 ). The nose clip and mouth- 
piece setup were able to fit 32 and 64 channel head coils at all sites. 
Researchers in the participating site were trained on-site by the lead 
site for the procedure of the CVR experiment. With proper preparation 
prior to each experiment, the setup time of nose clip and mouthpiece 
for the subjects were 3-5min before the CVR scan. Out of the 40 CVR 
experiments in the scan-rescan reproducibility study, only two failed 
to provide usable datasets due to technical error (CO2 air was not de- 
livered) and subject not cooperating (subject pushed mouthpiece out 
during the scan), suggesting the effectiveness of the training. The CVR 
analysis training were conducted as an online webinar, and all sites were 
able to follow the instructions and generate CVR mapping results. 
5. Conclusion 
The present study evaluated reliability of CVR quantification using 
CO2 inhalation and BOLD MR imaging. The CO2-CVR values obtained 
have demonstrated good inter-rater, inter-scanner, and test-retest relia- 
bilities in healthy volunteers. These findings suggest that CO2-CVR can 
be a reliable imaging biomarker of vascular function in the brain, and 
provide important reference for its applications in future multi-site and 
longitudinal observational studies and clinical trials. 
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